ReviewNature reviews. Genetics2019
Current and future perspectives of liquid biopsies in genomics-driven oncology.
Review in Nature reviews. Genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 860 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Breast Cancer Liquid Biopsy Stratification
Molecular Profiling and Dynamic Changes of Circulating Tumor DNA in Unresectable Locally Advanced Non-small Cell Lung Cancer
Early Detection of Stomach Cancer With a Liquid Biopsy Based on Exosomal Micro-RNA
Director, Department of Pathology, Jiangsu Provincial People's Hospital
Who cites it
860 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- CircZNF609 as a potential prognostic biomarker across multiple cancers: a systematic review and meta-analysis with ceRNA network exploration.Frontiers in oncology · 2026Pooled it
- DNA-Based Liquid Biopsy for Evaluating Surgical and Postsurgical Outcomes in Gynecologic Malignancies: A Systematic Review.Journal of clinical laboratory analysis · 2026Pooled it
- Liquid biopsy and health-related quality of life in cancers: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Pooled it
- Innovative technologies and their clinical prospects for early lung cancer screening.Clinical and experimental medicine · 2025Pooled it
- Liquid biopsy reveals the immune status and protein profiles linked to CTC burden and clinical outcomes in metastatic breast cancer.Journal of experimental & clinical cancer research : CR · 2026Trial
- Blood Sample Collection in Randomized Controlled Trials for Biomarker Discovery and Validation: Experience of the PREOPANC-2 Trial.Annals of surgical oncology · 2025Trial
- High-quantity capture of heterogeneous circulating tumor cellsMaterials today. Bio · 2026Article
- Finger-actuated microfluidic device for point-of-care circulating cell-free nucleic acid extraction.Lab on a chip · 2026Article
- Analytical and Clinical Validation of the Oncomine Dx Express Test, an In Vitro Diagnostic-Labeled Assay, for Genomic Profiling of FFPE Tumor Samples.Molecular diagnosis & therapy · 2026Article
- Towards a systematic understanding of the diverse subtypes, biogenesis and functions of large extracellular vesicles.Nature reviews. Molecular cell biology · 2026Review
- Immunomagnetic-MXene Bifunctional Probes for Ultrasensitive and Specific Terahertz Metasensing of Tumor-Derived Exosomes.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Analysis of cell-free DNA in lymphomas: from sample collection to genotyping and minimal residual disease monitoring.Blood advances · 2026Review
- Beyond the Needle: Is Liquid Biopsy the Future of Veterinary Medicine?International journal of molecular sciences · 2026Review
- The mechanism of malignant progression in extramammary Paget's disease (EMPD): hallmarks of EMPD.Medical molecular morphology · 2026Review
- Liquid biopsy in bladder cancer: towards precision oncology.Journal of translational medicine · 2026Review
- Review
- Beyond CA-125: circulating cell-free DNA as the next-generation biomarker in ovarian malignancy.BMC cancer · 2026Article
- Liquid biopsy: current applications and future directions.Molecular biomedicine · 2026Review
- Trustworthy Agentic AI in Bioinformatics: From Workflow Automation to Traceable and Validated Biological Inference.Biology · 2026Review
- Molecular sampling limits of ctDNA detection in clinical plasma samples.The journal of liquid biopsy · 2026Article
800 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Precision oncology seeks to leverage molecular information about cancer to improve patient outcomes. Tissue biopsy samples are widely used to characterize tumours but are limited by constraints on sampling frequency and their incomplete representation of the entire tumour bulk. Now, attention is turning to minimally invasive liquid biopsies, which enable analysis of tumour components (including circulating tumour cells and circulating tumour DNA) in bodily fluids such as blood. The potential of liquid biopsies is highlighted by studies that show they can track the evolutionary dynamics and heterogeneity of tumours and can detect very early emergence of therapy resistance, residual disease and recurrence. However, the analytical validity and clinical utility of liquid biopsies must be rigorously demonstrated before this potential can be realized.
Indexed as
Identifiers
30410101What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.